Menin Inhibition With Revumenib for  KMT2A  -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Issa, Ghayas C.; Aldoss, Ibrahim; Thirman, Michael J.; DiPersio, John F.; Arellano, Martha; Blachly, James S.; Mannis, Gabriel N.; Perl, Alexander E.; Dickens, David S.; McMahon, Christine M.; Traer, Elie; Zwaan, C. Michel; Grove, Carolyn; Stone, Richard M.; Shami, Paul J.; Mantzaris, Ioannis; Greenwood, Matthew; Shukla, Neerav; Cuglievan, Branko; Kovacsovics, Tibor; Gu, Yu; Bagley, Rebecca G.; Madigan, Kate; Chudnovsky, Yakov; Nguyen, Huy Van; McNeer, Nicole; Stein, Eytan M.; Wei, Andrew H.; Fleming, Shaun; Sabins, Himalee; Aldoss, Ibrahim; Kovacsovics, Tibor; Stone, Richard M.; Arellano, Martha; Patel, Manish R.; Talati, Chetasi; Chen, Jing; Nachmias, Boaz; Heiblig, Maël; Fernandez, P; Arnan-Sangerman, Montserrat; Stein, Eytan M.; Mantzaris, Ioannis; Blachly, James S.; Traer, Elie; Zwaan, C. Michael; Wolach, Ofir; Marconi, Giovanni; Bajel, Ashish; Grove, Carolyn; Mannis, Gabriel N.; Schuh, Andre C.; Thirman, Michael J.; Byrd, John; McMahon, Christine M.; Dickens, David S.; Perl, Alexander E.; Greenwood, Matthew; Issa, Ghayas C.; Whitlock, James A.; Shami, Paul J.; DiPersio, John F.

doi:10.1200/jco.24.00826

articleJournal of Clinical OncologyAug 9, 2024HYBRID OA

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

GCGhayas C. Issa IAIbrahim Aldoss MJMichael J. Thirman JFJohn F. DiPersio MAMartha Arellano

The University of Texas MD Anderson Cancer Center · City Of Hope National Medical Center · +25 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with KMT2A -rearranged ( KMT2Ar ) acute leukemia. Here, we evaluated the activity of revumenib in individuals with relapsed/refractory (R/R) KMT2Ar acute leukemia. METHODS AUGMENT-101 is a phase I/II, open-label, dose-escalation and expansion study of revumenib conducted across 22 clinical sites in five countries (ClinicalTrials.gov identifier: NCT04065399 ). We report results from the phase II, registration-enabling portion. Individuals age ≥30 days with R/R KMT2Ar acute leukemia or with AML and nucleophosmin 1…

Citation impact

171

total citations

FWCI: 69.39
Percentile: 100%
References: 23

Citations per year

Authors

62

Topics & keywords

Topics

Keywords

Augment
Medicine
Refractory (planetary science)
Leukemia
Cancer research
Oncology
Internal medicine
Biology

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.